Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 19/20 | 0.68 |
| ▸ | PRKDC | P78527 | 5/20 | 0.68 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | IKBKB | O14920 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5684569 | 0.89 | ATR (0.63) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL24248259 | 0.88 | ATR (0.67) | ATRPRKDCATMCYP3A4IKBKB | |
| SCHEMBL2486385 | 0.87 | ATR (0.70) | ATRCYP3A4 | |
| SCHEMBL14525246 | 0.87 | ATR (0.65) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL11908281 | 0.87 | ATR (0.67) | ATRPRKDCATM | |
| SCHEMBL11908296 | 0.87 | ATR (0.67) | ATRPRKDCATMCYP3A4 | |
| SCHEMBL319167 | 0.86 | ASIC3 (0.57) | ATRPRKDCATMCYP3A4IKBKB | |
| SCHEMBL11906967 | 0.85 | ATR (0.67) | ATRPRKDCATM | |
| SCHEMBL23703073 | 0.85 | ATR (0.67) | ATRPRKDCATM | |
| SCHEMBL3462610 | 0.85 | ATR (0.63) | ATRPRKDCATMCYP3A4IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199123-B2 | Pyrazine compounds as transforming growth factor (TGF) compounds | PFIZER INC. (US) | 2007-04-03 | — | — | US | claimed |
| EP-1606267-A1 | PYRAZINE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2004080982-A1 | PYRAZINE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-09-23 | — | — | WO | claimed |
| US-20040180905-A1 | for treating cancer and fibrotic diseases | PFIZER INC | 2004-09-16 | — | — | US | claimed |
| US-12195490-B2 | STRAD-binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-14 | — | — | US | disclosed |
| CN-115916966-A | STRAD binding agents and uses thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| EP-4097223-A1 | STRAD-BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4059932-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-3354650-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11179394-B2 | Method for treating cancer using a combination of Chk1 and ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-11-23 | — | — | US | disclosed |
| US-11110086-B2 | Compounds useful as inhibitors of ATR kinase and combination therapies thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-09-07 | — | — | US | disclosed |
| US-7199123-B2 | Pyrazine compounds as transforming growth factor (TGF) compounds | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199123-B2 | Pyrazine compounds as transforming growth factor (TGF) compounds | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1606267-A1 | PYRAZINE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1501514-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004080982-A1 | PYRAZINE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040180905-A1 | for treating cancer and fibrotic diseases | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| WO-2003093297-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11110086-B2 | Compounds useful as inhibitors of ATR kinase and combination therapies thereof | ATR, CHEK1, CHEK2 | ATR 1/4885PRKDC 20/4885ATM 16/4885 |
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | ATR 556/4885PRKDC 124/4885ATM 398/4885 |
| US-11179394-B2 | Method for treating cancer using a combination of Chk1 and ATR inhibitors | CHEK1, CHEK2, ATR | ATR 3/4885PRKDC 73/4885ATM 7/4885 |
| US-20040180905-A1 | for treating cancer and fibrotic diseases | SMAD3, SMAD2, TGFBR2 | ATR 975/4885PRKDC 2821/4885ATM 552/4885 |
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885PRKDC 23/4885ATM 39/4885 |
| US-12195490-B2 | STRAD-binding agents and uses thereof | STRAP, STRA6, PLAUR | ATR 3836/4885PRKDC 467/4885ATM 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.